Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia

Zheng Ge, Qi Han, Yan Gu, Qinyu Ge, Jinlong Ma, Justin Sloane, Guofeng Gao, Kimberly J. Payne, Laszlo Szekely, Chunhua Song, Sinisa Dovat

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Mutations and single nucleotide polymorphisms of AT-rich interactive domain-containing protein 5B (ARID5B) are involved in the oncogenesis of acute lymphoblastic leukemia (ALL) and treatment outcomes. However, ARID5B expression and clinical significance in ALL remain unclear. We found ARID5B is significantly down-regulated in ALL compared to healthy bone marrow controls. ARID5B also interacts with PHD finger protein 2 (PHF2). Low expression of ARID5B (ARID5B low ) or ARID5B and PHF2 (ARID5B low PHF2 low ) is correlated with the markers of cell proliferation and poor prognosis in ALL patients. Ikaros directly regulates ARID5B expression in ALL. Restoring Ikaros function by Casein Kinase II inhibition also promotes ARID5B expression through recruitment of trimethylation of lysine 4 on histone H3 (H3K4me3) at its promoter region. In summary, our data show that aberrant expression of ARID5B and PHF2 is related to leukemic cell proliferation and several poor prognostic markers. Our data indicate ARID5B low expression, particularly ARID5B low PHF2 low expression, is linked to Ikaros dysfunction and involved in the oncogenic effect of high-risk ALL, which may represent a high-risk subgroup of ALL.

Original languageEnglish (US)
Article number84
JournalOncogenesis
Volume7
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Fingers
Proteins
Protein Domains
Cell Proliferation
Casein Kinase II
Genetic Promoter Regions
Histones
Lysine
Single Nucleotide Polymorphism
Carcinogenesis
Bone Marrow

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Cancer Research

Cite this

Ge, Zheng ; Han, Qi ; Gu, Yan ; Ge, Qinyu ; Ma, Jinlong ; Sloane, Justin ; Gao, Guofeng ; Payne, Kimberly J. ; Szekely, Laszlo ; Song, Chunhua ; Dovat, Sinisa. / Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia. In: Oncogenesis. 2018 ; Vol. 7, No. 11.
@article{b195f824e46648789905abf699cdbd6c,
title = "Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia",
abstract = "Mutations and single nucleotide polymorphisms of AT-rich interactive domain-containing protein 5B (ARID5B) are involved in the oncogenesis of acute lymphoblastic leukemia (ALL) and treatment outcomes. However, ARID5B expression and clinical significance in ALL remain unclear. We found ARID5B is significantly down-regulated in ALL compared to healthy bone marrow controls. ARID5B also interacts with PHD finger protein 2 (PHF2). Low expression of ARID5B (ARID5B low ) or ARID5B and PHF2 (ARID5B low PHF2 low ) is correlated with the markers of cell proliferation and poor prognosis in ALL patients. Ikaros directly regulates ARID5B expression in ALL. Restoring Ikaros function by Casein Kinase II inhibition also promotes ARID5B expression through recruitment of trimethylation of lysine 4 on histone H3 (H3K4me3) at its promoter region. In summary, our data show that aberrant expression of ARID5B and PHF2 is related to leukemic cell proliferation and several poor prognostic markers. Our data indicate ARID5B low expression, particularly ARID5B low PHF2 low expression, is linked to Ikaros dysfunction and involved in the oncogenic effect of high-risk ALL, which may represent a high-risk subgroup of ALL.",
author = "Zheng Ge and Qi Han and Yan Gu and Qinyu Ge and Jinlong Ma and Justin Sloane and Guofeng Gao and Payne, {Kimberly J.} and Laszlo Szekely and Chunhua Song and Sinisa Dovat",
year = "2018",
month = "11",
day = "1",
doi = "10.1038/s41389-018-0095-x",
language = "English (US)",
volume = "7",
journal = "Oncogenesis",
issn = "2157-9024",
publisher = "Nature Publishing Group",
number = "11",

}

Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia. / Ge, Zheng; Han, Qi; Gu, Yan; Ge, Qinyu; Ma, Jinlong; Sloane, Justin; Gao, Guofeng; Payne, Kimberly J.; Szekely, Laszlo; Song, Chunhua; Dovat, Sinisa.

In: Oncogenesis, Vol. 7, No. 11, 84, 01.11.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia

AU - Ge, Zheng

AU - Han, Qi

AU - Gu, Yan

AU - Ge, Qinyu

AU - Ma, Jinlong

AU - Sloane, Justin

AU - Gao, Guofeng

AU - Payne, Kimberly J.

AU - Szekely, Laszlo

AU - Song, Chunhua

AU - Dovat, Sinisa

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Mutations and single nucleotide polymorphisms of AT-rich interactive domain-containing protein 5B (ARID5B) are involved in the oncogenesis of acute lymphoblastic leukemia (ALL) and treatment outcomes. However, ARID5B expression and clinical significance in ALL remain unclear. We found ARID5B is significantly down-regulated in ALL compared to healthy bone marrow controls. ARID5B also interacts with PHD finger protein 2 (PHF2). Low expression of ARID5B (ARID5B low ) or ARID5B and PHF2 (ARID5B low PHF2 low ) is correlated with the markers of cell proliferation and poor prognosis in ALL patients. Ikaros directly regulates ARID5B expression in ALL. Restoring Ikaros function by Casein Kinase II inhibition also promotes ARID5B expression through recruitment of trimethylation of lysine 4 on histone H3 (H3K4me3) at its promoter region. In summary, our data show that aberrant expression of ARID5B and PHF2 is related to leukemic cell proliferation and several poor prognostic markers. Our data indicate ARID5B low expression, particularly ARID5B low PHF2 low expression, is linked to Ikaros dysfunction and involved in the oncogenic effect of high-risk ALL, which may represent a high-risk subgroup of ALL.

AB - Mutations and single nucleotide polymorphisms of AT-rich interactive domain-containing protein 5B (ARID5B) are involved in the oncogenesis of acute lymphoblastic leukemia (ALL) and treatment outcomes. However, ARID5B expression and clinical significance in ALL remain unclear. We found ARID5B is significantly down-regulated in ALL compared to healthy bone marrow controls. ARID5B also interacts with PHD finger protein 2 (PHF2). Low expression of ARID5B (ARID5B low ) or ARID5B and PHF2 (ARID5B low PHF2 low ) is correlated with the markers of cell proliferation and poor prognosis in ALL patients. Ikaros directly regulates ARID5B expression in ALL. Restoring Ikaros function by Casein Kinase II inhibition also promotes ARID5B expression through recruitment of trimethylation of lysine 4 on histone H3 (H3K4me3) at its promoter region. In summary, our data show that aberrant expression of ARID5B and PHF2 is related to leukemic cell proliferation and several poor prognostic markers. Our data indicate ARID5B low expression, particularly ARID5B low PHF2 low expression, is linked to Ikaros dysfunction and involved in the oncogenic effect of high-risk ALL, which may represent a high-risk subgroup of ALL.

UR - http://www.scopus.com/inward/record.url?scp=85056414388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056414388&partnerID=8YFLogxK

U2 - 10.1038/s41389-018-0095-x

DO - 10.1038/s41389-018-0095-x

M3 - Article

VL - 7

JO - Oncogenesis

JF - Oncogenesis

SN - 2157-9024

IS - 11

M1 - 84

ER -